Loading
A phase 1/2 trial of Silevertinib in non-small-cell lung cancer and small-cell lung cancer, run by Black Diamond Therapeutics, Inc., active and no longer recruiting.
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations is a phase 1/2 interventional study registered as NCT05256290 by Black Diamond Therapeutics, Inc., with 200 participants planned, started 2022-03-31 and due to reach its primary completion in 2025-11-03. Interventions recorded: silevertinib (BDTX-1535) monotherapy. Conditions listed: Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/